Highest ever quarterly sales at 586 crores.
US market grew by 16 % QoQ
Filed DMF for one products and planning to file another DMF for backward integration this quarter.
Cash balance at 688 crores
Consistent improvement in gross and EBITDA margins.
Teva facility is yet to break even. Operating leverage will kick in once sales increase at Teva facility. Expecting more contribution from Teva in Q4. The company seemed confident in future growth.
Expecting 600 crores sales from Teva facility in FY 25. Management sees a lot of prospects in US markets. Mentioned that they had just touched the tip of an iceberg. Sees a lot of prospects in the US market. Focussing on cough, allergy, digestive and cold OTC markets.
Spent 29.4 crores on R & D which is 1.8 % of sales.
Capex of 160 crores for the 9 months. Expecting a total capex of 250 – 300 crores over the next 2 years including the cost of acquisition of Teva. Nothing concrete on acquisition in Europe.
In US, the flu season starts in winter and a part of the QoQ growth could be attributed to this.
Subscribe To Our Free Newsletter |